Should I Buy ADMA? ADMA 2026 Analysis

Should You Buy ADMA Biologics Inc (ADMA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

16.430

1 Day change

3.07%

52 Week Range

25.670

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Good buy right now for an impatient trader: price is sitting just above the key pivot (17.096) with improving momentum (MACD expanding > 0), creating a favorable near-term entry/risk setup.
Institutional behavior is supportive: hedge funds are aggressively increasing exposure (+719.51% QoQ), which often precedes continuation or trend reversal moves.
Main trade levels: upside objectives near R1 17.776 then R2 18.196; downside line-in-the-sand is S1 16.416.

Technical Analysis

Trend/moving averages: Bearish stack (SMA_200 > SMA_20 > SMA_5) indicates the broader trend is still pressured, so this is a momentum-reversal/early-entry style buy rather than a confirmed uptrend buy.
Momentum: MACD histogram 0.0369 and positively expanding suggests bullish momentum is building.
RSI: RSI_6 at 58.62 is neutral-to-slightly-bullish (not overbought), leaving room for continuation.
Key levels: Pivot 17.096 (current price 17.52 above pivot = constructive). Resistance at 17.776 (R1) then 18.196 (R2). Support at 16.416 (S1) then 15.996 (S2).
Intellectia Proprietary Trading Signals: Intellectia Proprietary Trading Signals
- AI Stock Picker: No signal on given stock today.
- SwingMax: No signal on given stock today.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Positioning (Open Interest): Put/Call OI ratio 0.32 is bullish (more calls outstanding than puts), signaling generally constructive sentiment/positioning.
Flow (Volume): Put/Call volume ratio 1.31 is bearish for the day (puts traded > calls), suggesting some near-term hedging or caution.
Activity spike: today’s options volume is ~24.39x the 30-day average, indicating unusually high interest.
Volatility: IV (30d) 53.52 vs HV 52.81 is roughly in-line; IV percentile 34.4 and IV rank 9.92 suggest options are not extremely expensive versus recent history.

Technical Summary

Sell

Buy

Positive Catalysts

- Hedge funds are accumulating aggressively (+719.51% QoQ buying), a strong sentiment tailwind.
- Technical momentum is improving (MACD expanding above zero) while RSI is not stretched.
- Financials show continued growth with improving profitability metrics (notably gross margin expansion).
- Pattern-based forward tendency provided: +4.07% expected bias over the next month (probabilistic, not guaranteed).

Neutral/Negative Catalysts

- Broader trend remains bearish per moving averages (SMA_200 > SMA_20 > SMA_5), meaning rallies can face supply until trend fully flips.
- Options tape shows near-term caution (put volume > call volume today).
- No fresh news catalysts in the last week to force a rapid re-rating.
- No supportive insider buying trend flagged (insiders neutral).

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 134.224M, +12.00% YoY (solid top-line growth).
Net income: 36.428M, +1.45% YoY (profits growing, but slower than revenue).
EPS: 0.15, ~flat YoY (earnings growth not yet strongly translating to per-share acceleration).
Gross margin: 56.31%, +13.16% YoY (notable margin expansion is a clear quality positive).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating trend or price target change data was provided in the dataset, so no recent upgrade/downgrade momentum can be confirmed.
Wall Street pro view (inferred from available data only): Pros would emphasize accelerating revenue and strong gross margin improvement; cons would point to modest net income growth and the still-bearish longer-term technical trend.
Political/influential trading check: No recent congress trading data available in the last 90 days.

1 Analyst Rating

Wall Street analysts forecast ADMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADMA is 30 USD with a low forecast of 30 USD and a high forecast of 30 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 15.940

Low

Averages

High

Current: 15.940

Low

Averages

High

Raymond James

Strong Buy

maintain

$25 -> $32

AI Analysis

2025-05-08

Reason

Raymond James

Price Target

$25 -> $32

AI Analysis

2025-05-08

maintain

Strong Buy

Reason

Raymond James raised the firm's price target on Adma Biologics to $32 from $25 and keeps a Strong Buy rating on the shares. Adma's Q1 missed slightly from a non-recurring event and higher spend, but all the fundamentals are trending positively and 2025-2026 guidance was raised still with a lot of room for upside, the analyst tells investors in a research note. The firm adds that tariffs are "not an issue" for Adma.

Cantor Fitzgerald

Kristen Kluska

Buy

Reiterates

$25

2025-03-04

Reason

Cantor Fitzgerald

Kristen Kluska

Price Target

$25

2025-03-04

Reiterates

Buy

Reason

ADMA Should I Buy

ADMA Should I Buy

Should You Buy ADMA Biologics Inc (ADMA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch